Topic

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Articles

As Brexit talks intensify, bio/pharma companies from both the UK and EU need to consider and aim to prepare for all scenarios.

No Business, Like Brexit Business

The protocol on Northern Ireland (NI) once Brexit has been completed has received mixed opinions in industry, according to various press releases.

Mixed Opinions on Post-Brexit Approach to Northern Ireland Protocol

ABPI has issued a statement noting that it shares the ambition of the United Kingdom’s government, as set out in its published approach to the negotiations for the future relationship with the European Union (EU).


Industry Responds to UK Government’s Approach to Future Relationship with EU

According to executive search firm Odgers Berndtson, its recent poll has highlighted that senior executives in life sciences believe there is a positive future for the United Kingdom’s sector outside the European Union.


The Future is Bright for Post-Brexit UK Life Sciences, Notes Poll

Sean Milmo is a freelance writer based in Essex, UK.

The UK and Europe are entering a transitional period, which will involve negotiations across the board, including those on the pharma regulatory landscape.

Brexit: What Happens Next for Pharma?

In 2020, European regulators are expected to start to be even more active in encouraging drugs innovations rather than hindering them through legal restrictions.


European Regulators Strive to Make Up for Lost Ground

As the UK heads to the polls for an unusual December general election, industry issues manifestos on medicines while Europe rejoices some movement … finally.

‘Polling’ All the Way

Vincenzo Salvatore is team leader Healthcare and Life Sciences Focus Team, BonelliErede.

Despite preparative work by the bio/pharma industry, any Brexit scenario will result in regulatory implications and increased costs.


The Cost of Brexit

The new location was established to ensure uninterrupted support for clients’ trials in both the United Kingdom and Europe if the UK leaves the European Union on Oct. 31, 2019, especially in the event of a no-deal Brexit.

Yourway Opens New Slovakia Location to Secure Client Trials in Case of No-Deal Brexit

As the world awaits the outcome of Brexit, a presentation taking place at CPhI Worldwide in Frankfurt, Germany will delve deeper into the implications of each potential scenario on the pharma industry.

Bio/Pharma and Brexit